Aravive (NASDAQ:ARAV) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Aravive (NASDAQ:ARAV) from a buy rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States. “

A number of other analysts have also recently weighed in on ARAV. ValuEngine cut shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Wedbush set a $269.00 target price on shares of United Therapeutics and gave the stock a buy rating in a research note on Monday, April 8th. Finally, Piper Jaffray Companies boosted their target price on shares of Boot Barn from $33.00 to $41.00 and gave the stock an overweight rating in a research note on Monday, May 13th.

NASDAQ ARAV opened at $5.90 on Wednesday. The business’s fifty day moving average is $5.93. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $12.60. The company has a current ratio of 7.78, a quick ratio of 7.78 and a debt-to-equity ratio of 0.17.

Aravive (NASDAQ:ARAV) last posted its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.44. The company had revenue of $1.70 million for the quarter. As a group, sell-side analysts predict that Aravive will post -2.19 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG bought a new stake in shares of Aravive during the fourth quarter worth $78,000. Millennium Management LLC bought a new stake in shares of Aravive in the fourth quarter worth $86,000. D. E. Shaw & Co. Inc. bought a new stake in shares of Aravive in the fourth quarter worth $73,000. Two Sigma Advisers LP bought a new stake in shares of Aravive in the fourth quarter worth $87,000. Finally, Two Sigma Investments LP bought a new stake in shares of Aravive in the fourth quarter worth $124,000. 27.57% of the stock is currently owned by hedge funds and other institutional investors.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Featured Story: What is a Derivative?

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.